Safety and Performance Study of the FAST-FIX FLEX System for Meniscal Repairs and Meniscal Transplantations

Sponsor
Smith & Nephew, Inc. (Industry)
Overall Status
Recruiting
CT.gov ID
NCT04903106
Collaborator
(none)
130
5
20.3
26
1.3

Study Details

Study Description

Brief Summary

This study is a post-market follow-up study (PMCF). The data collected will serve the purpose of confirming the safety and performance of the FAST-FIX FLEX device, used according to the indicated for use (IFU) for meniscal repair and meniscal transplantations. Data will be collected on patients prior to surgery, at surgery and for 12 months after surgery.

Condition or Disease Intervention/Treatment Phase
  • Device: FAST-FIX FLEX Meniscal Repair System
  • Device: FAST-FIX FLEX Meniscal Repair System

Detailed Description

This PMCF study is to satisfy the post-market surveillance obligations to the European Medical Device Regulation (EU MDR 2017/745). The data collected will serve the purpose of confirming the safety and performance of the FAST-FIX FLEX device, used according to the indicated for use (IFU) for meniscal repair and meniscal transplantations. Data will be collected on patients prior to surgery, at surgery and for 12 months after surgery.

The objectives of the study are to assess the clinical success rate of both clinical indications (meniscal repair and meniscal allograft transplantations) and the performance and safety of the FAST-FIX FLEX meniscal repair system.

The sample size for this study is precision-based and not based on statistical power considerations. Thus, no formal statistical hypothesis is formulated. The sample size for this study is determined based on the feasibility of recruitment, enrolment and follow-up considerations.

The primary endpoint upon which the sample size is determined is defined by the rate of reoperation after at 12 months.

Additionally, secondary endpoints in this study assess success rate, meniscus healing and clinical performance of Patient Reported Outcomes (PRO) for meniscal repair and meniscal allograft transplantations.

Study Design

Study Type:
Observational
Anticipated Enrollment :
130 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
A Prospective, Multi-center Clinical Study to Evaluate the Safety and Performance of the FAST-FIX FLEX System for Meniscal Repairs (MR) and Meniscal Allograft Transplantations (MAT)
Actual Study Start Date :
Jan 20, 2022
Anticipated Primary Completion Date :
Sep 26, 2022
Anticipated Study Completion Date :
Sep 29, 2023

Arms and Interventions

Arm Intervention/Treatment
Meniscal Tear

Subject requires a meniscus repair concerning the red-red or red-white zones for acute or chronic 1-, 2- or 3-segment lesions, with or without associated anterior cruciate ligament (ACL) reconstruction.

Device: FAST-FIX FLEX Meniscal Repair System
Standard of care surgery in which the meniscus is repaired using FAST-FIX FLEX device.

Meniscal Insufficiency

Subject requires a MAT for symptomatic meniscal insufficiency (load related pain and swelling in the compartment undergoing meniscectomy) for which conservative treatment has failed.

Device: FAST-FIX FLEX Meniscal Repair System
Standard of care surgery in which the FASTFIX FLEX device is used during the meniscal allograft transplantation procedure.

Outcome Measures

Primary Outcome Measures

  1. Clinical Success [12 months]

    Rate of reoperation due to meniscal repair failure at 12 months postoperative

Secondary Outcome Measures

  1. Clinical Success [6 months]

    Rate of reoperation due to meniscal repair failure at 6 months postoperative

  2. Clinical Success [6 months and 12 months]

    Rate of reoperation due to meniscal allograft transplantation failure at 6 months & 12 months post-operative

  3. Meniscal Healing [Pre-operatively, 6 months and 12 months]

    MRI to assess structural integrity and meniscal healing at 6 months and 12 months

  4. Change in Patient Reported Outcome (PRO): International Knee Documentation Committee (IKDC) Subjective Score [Pre-operatively, 6 months and 12 months]

    The International Knee Documentation Committee (IKDC) Subjective score was developed to detect improvement or deterioration in symptoms, function, and sports activities due to knee impairment, including patients with meniscal injuries. There are three domains: symptoms, including pain, stiffness, swelling, locking/catching, and giving way (7 items), sports and daily activities (10 items), and current knee function and knee function prior to knee injury (1 item, not included in the score). Responses vary for each item. The possible score ranges from 0-100,where 100 = no limitation with daily or sporting activities and the absence of symptoms.

  5. Change in Patient Reported Outcome (PRO): Lysholm Score [Pre-operatively, 6 months and 12 months]

    This tool measures the domains of symptoms and complaints and functioning of daily activities. The scale consists of 8 items and is scaled from 0 to 100, with a higher score indicating fewer symptoms and higher level of functioning.

  6. Change in Patient Reported Outcome (PRO): EuroQol 5 Dimension 5 Level (EQ-5D-5L) [Pre-operatively, 6 months and 12 months]

    The EQ-5D-5L descriptive system comprises the following dimensions: Mobility, Self-Care, Usual Pain/ Discomfort and Anxiety/ Depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems, and extreme problems.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 70 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  1. Subject provides written informed consent for study participation using an independent ethical committee (IEC) / institutional review board (IRB) approved consent form;

  2. Subject is between eighteen (18) and seventy (70) years of age, inclusive at the time of screening;

  3. Subject is willing and able to participate in required follow-up visits and is able to complete study activities;

  4. Subject requires a meniscal repair or meniscal allograft transplantation;

  5. Subject is suitable to participate in the study in the opinion of the Investigator.

Meniscal Repair ONLY:
  1. Subject requires a meniscus repair concerning the red-red or red- white zones for acute or chronic 1-, 2- or 3-segment lesions, with or without associated anterior cruciate ligament (ACL) reconstruction.
Meniscal Allograft Transplantation ONLY:
  1. Subject requires a MAT for symptomatic meniscal insufficiency (load- related pain and swelling in the compartment undergoing meniscectomy) for which conservative treatment has failed.
Exclusion Criteria:
  1. Contraindications (per the FAST-FIX FLEX IFU) or hypersensitivity to the use of the FAST-FIX FLEX implant material. Where material sensitivity is suspected, appropriate tests should be made and sensitivity ruled out prior to implantation;

  2. Participation in the treatment period of another clinical trial within thirty (30) days of operative visit, or during the study;

  3. Women who are pregnant, nursing, or of child-bearing potential who are not utilizing highly effective birth control measures;

  4. Any subject that meets the definition of a Vulnerable Subject per ISO 14155:2011 Section 3.44;

  5. Subjects with a history of poor compliance with medical treatment, physical therapy (PT)/rehabilitation, or clinical study participation;

  6. Patients with irreparable meniscal tears (i.e. grade 3 outerbridge osteoarthritis or greater, serious defects, multiple tears);

  7. Patients with multi-ligament tears (i.e. ACL tear is not associated with lateral collateral ligament (LCL) or medial collateral ligament (MCL) tears);

  8. Performance of a significant concomitant procedure, specifically a cartilage repair or restoration (excluding ACL reconstruction or repair) intended as a therapeutic intervention on the study knee;

  9. History of ipsilateral knee surgery, septic joint, or fracture;

  10. Pathological conditions in the soft tissue that would prevent secure fixation of the device;

  11. Physical conditions which would eliminate, or tend to eliminate, adequate anchor support or retard healing;

  12. The presence of infection;

  13. Conditions which would limit the patient's ability or willingness to restrict activities or follow directions during the healing period;

  14. Malalignment: genu varus and genu valgus angles greater than 5° with respect to the normal axis to indicate malalignment;

  15. Patients who had an Ahlback grade greater than II;

  16. Patients with a body mass index larger than 30.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Rush University Medical Center Chicago Illinois United States 60612
2 Hospital for Special Surgery New York New York United States 10021
3 Fremantle Hospital Fremantle Western Australia Australia 6160
4 Sporthopaedicum Berlin Charlottenburg Berlin Germany 10627
5 Robert Jones and Agnes Hunt Orthopaedic Hospital NHS Foundation Trust Oswestry Shropshire United Kingdom SY10 7AG

Sponsors and Collaborators

  • Smith & Nephew, Inc.

Investigators

  • Study Chair: Stephan Mangin, Smith & Nephew, Inc.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Smith & Nephew, Inc.
ClinicalTrials.gov Identifier:
NCT04903106
Other Study ID Numbers:
  • FAST-FIX FLEX.2020.09
First Posted:
May 26, 2021
Last Update Posted:
Apr 6, 2022
Last Verified:
Mar 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
Yes
Product Manufactured in and Exported from the U.S.:
Yes
Keywords provided by Smith & Nephew, Inc.

Study Results

No Results Posted as of Apr 6, 2022